CAS: 123040-69-7; 6-Chloro-4-Methyl-3-Oxo-N-(Quinuclidin-3-yl)-3,4-Dihydro-2H-Benzo[b][1,4]Oxazine-8-Carboxamide

上下游产品

CAS号4068-78-4 5-氯水杨酸甲酯 | CAS号5043-81-2 3-氨基-5-氯-2-羟基苯甲酸甲酯 | CAS号123040-75-5 6-氯-3,4-二氢-3-氧代... | CAS号5043-79-8 5-氯-2-羟基-3-硝基苯甲酸甲酯 | CAS号123040-79-9 6-氯-4-甲基-3-氧代-3... | CAS号141761-83-3 6-氯-3,4-二氢-4-甲基... | CAS号76883-48-2 (RS)-3-amino-1-... | CAS号123040-50-6 6-CHLORO-3,4-DI...

5-氯-2-羟基苯甲酸甲酯置于sodium Hydroxide,氯化亚砜,硫酸,硝酸,铁粉,碳酸氢钠,Potassium Carbonate,氯化铵,N,N-二甲基甲酰胺体系中,用 乙醇,氯仿,1,2-二氯乙烷,N,N-二甲基甲酰胺,甲苯 用作溶剂,化学反应 16.0H,反应生成盐酸阿扎司琼
参考文献:3,4-二氢-3-氧代-1,4-苯并恶嗪-8-羧酰胺衍生物的合成和药理作用,它是一类新型的5-羟色胺-3(5-Ht3)高效受体拮抗剂.
标题:3,4-二氢-3-氧代-1,4-苯并恶嗪-8-羧酰胺衍生物的合成和药理作用,它是一类新型的5-羟色胺-3(5-Ht3)高效受体拮抗剂.
摘要:合成了一系列3,4-二氢-3-氧代-1,4-苯并恶嗪-8-羧酰胺衍生物,并通过其拮抗von Bezold-Jarish的能力评估了血清素3(5-Ht3)受体的拮抗活性. (bj)在大鼠中的作用.带有1-氮杂双环[2.2.2]辛-3-基部分作为基本功能的衍生物在8位羧酰胺上显示出比带有其他三个基本部分的衍生物更强的拮抗活性.该系列的构效关系表明,甲基和氯基分别更有效地取代了位置4和6.该系列中的代表性化合物15(y-25130)对bj效应表现出强大的拮抗活性(ed50 = 1.3微克/千克iv),对5-Ht3受体具有高亲和力(ki = 2).
Doi:10.1248/cpb.40.624

专利信息

专利号:US-8734846-B2
优先权日:2008-06-16
标 题 :Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles
发明人：ALI MIR M; HRKACH JEFF; ZALE STEPHEN E; ALVAREZ DE CIENFUEGOS LUIS
权利人:BIND BIOSCIENCES INC
摘要:This application provides nanoparticles and methods of making nanoparticles using pre-functionalized poly(ethylene glycol)(also referred to as PEG) as a macroinitiator for the synthesis of diblock copolymers. Ring opening polymerization yields the desired poly(ester)-poly (ethylene glycol)-targeting agent polymer that is used to impart targeting capability to therapeutic nanoparticles. This “polymerization fromâ€? approach typically employs precursors of the targeting agent wherein the reactivity of functional groups of the targeting agent is masked using protecting groups. Also described is a “coupling toâ€? that utilized the poly(ethylene glycol)-targeting agent conjugate where the targeting agent remains in its native un-protected form. This method uses “orthogonalâ€? chemistry that exhibit no cross reactivity towards functional groups typically found within targeting agents of interest.

专利号:US-2013035307-A1
优先权日:2010-01-26
标 题:Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers
发明人：PRESTWICH GLENN D; KENNEDY THOMAS P
权利人:UNIV UTAH RES FOUND; PRESTWICH GLENN D; KENNEDY THOMAS P
摘要:Described herein are methods for the treatment and prevention of tumor metastasis using alkylated and fluoroalkylated semi-synthetic glycosaminoglycan ethers (“SAGEsâ€?). The synthesis of sulfated alkylated and fluoroalkylated SAGEs is also described.

专利号:US-2008214827-A1
优先权日:2004-02-03
标 题:Synthesis of Cyanoimino-Benzoimidazoles
发明人：GOEHRING R RICHARD; WHITEHEAD JOHN; SHAO BIN
权利人:EURO CELTIQUE SA
摘要:Disclosed in certain embodiments is a process for synthesizing a compound of formula (V) and salts thereof.

专利号:US-9220714-B2
优先权日:2006-03-16
标 题 :Nitrofuran compounds for the treatment of cancer and angiogenesis
发明人：SAULNIER SHOLLER GISELLE L; SWAMY NARASIMHA; KALKUNTE STAYAN; SINGH RAKESH K; BRARD LAURENT; KIM KYU KWANG
权利人:WOMEN AND INFANTS HOSPITAL OF RHODE ISLAND; UNIV BROWN; WOMEN AND INFANTS HOSPITAL RHODE ISLAND
摘要:The invention is directed to the synthesis and use of nitrofuran compounds, especially Nifurtimox, as medicaments to treat cancer, especially neuroblastoma, and to inhibit angiogenesis. The invention also provides compositions, unit dosage forms, and kits comprising the compounds.

专利号:US-7309799-B2
优先权日:2004-06-01
标 题:Methods for the synthesis of milnacipran and congeners thereof
发明人：BUCHWALD STEPHEN L; SWAGER TIMOTHY M; RARIY ROMAN V
权利人:COLLEGIUM PHARMACEUTICAL INC
摘要:One aspect of the present invention relates to methods for synthesizing milnacipran or congeners thereof. Another aspect of the present invention relates to asymmetric methods for synthesizing enantiomerically enriched milnacipran or congeners thereof. The present invention also relates to methods for synthesizing intermediates useful in the non-asymmetric or asymmetric methods for synthesizing enantiomerically enriched milnacipran or congeners thereof.

专利号:US-2024382626-A1
优先权日:2023-05-16
标题 :Irradiation amenable liposomal dye aggregates and methods of synthesis and use thereof
发明人：PORTER TYRONE; STERN NOAH; TUNNELL JAMES; SHRESTHA BINITA
权利人:UNIV TEXAS
摘要:The present invention provides lipid nanoparticles that are amenable to an irradiation at a wavelength at or above 850 nm, have an absorption peak from about 850 to 1100 nm wavelength, and comprise a high transition temperature lipid and a dye (e.g., a J-aggregate of a dye). In some embodiments, the dye (e.g., J-aggregate of the dye) is encapsulated in the lipid nanoparticle. In various embodiments, the present invention also relates to compositions comprising said lipid nanoparticles and methods of generating said lipid nanoparticles and compositions thereof. The present invention further relates to methods relating to the said lipid nanoparticles for imaging, detection, and treatment of diseases or disorders (e.g., phototherapy) in a subject.